SCHEMBL20119978

SCHEMBL20119978

Cc1cc2c(NCc3nccs3)nc(Cl)nc2[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 1/20 0.44
TRPM5 Q9NZQ8 1/20 0.37
CLK1 P49759 1/20 0.35
CLK2 P49760 1/20 0.35
CLK3 P49761 1/20 0.35
DYRK1A Q13627 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
DYRK1B Q9Y463 1/20 0.35
KHK P50053 2/20 0.33
IGF1R P08069 1/20 0.33
PTGS2 P35354 1/20 0.33
PTK2 Q05397 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TLR7 Q9NYK1 1/20 0.32
CHRM4 P08173 1/20 0.32
PDE5A O76074 1/20 0.32
APP P05067 1/20 0.32
SYK P43405 1/20 0.31
MAP3K8 P41279 1/20 0.31
KDM1A O60341 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24390703 0.82 HRH4 (0.41) HRH4TRPM5CLK1CLK2CLK3
SCHEMBL22358637 0.82 HRH4 (0.41) HRH4TRPM5CLK1CLK2CLK3
SCHEMBL29833935 0.82 HRH4 (0.41) HRH4TRPM5CLK1CLK2CLK3
SCHEMBL29238786 0.82 HRH4 (0.41) HRH4TRPM5CLK1CLK2CLK3
SCHEMBL22358601 0.81 HRH4 (0.40) HRH4TRPM5CLK1CLK2CLK3
Hydrochloric Acid SCHEMBL22347057 0.81 HRH4 (0.40) HRH4TRPM5CLK1CLK2CLK3
Hydrochloric Acid SCHEMBL22347058 0.81 HRH4 (0.40) HRH4TRPM5CLK1CLK2CLK3
Hydrochloric Acid SCHEMBL29833931 0.81 HRH4 (0.40) HRH4TRPM5CLK1CLK2CLK3
Hydrochloric Acid SCHEMBL29833926 0.81 HRH4 (0.40) HRH4TRPM5CLK1CLK2CLK3
Hydrochloric Acid SCHEMBL29238825 0.81 HRH4 (0.40) HRH4TRPM5CLK1CLK2CLK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 HRH4 4263/4885TRPM5 4390/4885CLK1 3836/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 HRH4 4263/4885TRPM5 4390/4885CLK1 3836/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 HRH4 4263/4885TRPM5 4390/4885CLK1 3836/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 HRH4 4263/4885TRPM5 4390/4885CLK1 3836/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 HRH4 4263/4885TRPM5 4390/4885CLK1 3836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.